

Appendix A

Acknowledgement Receipt

The USPTO has received your submission at **12:02:40** Eastern Time on **17-FEB-2009** by Deposit Account: 190134.

\$ **180** fee paid by e-Filer via *RAM* with Confirmation Number: 11049.

eFiled Application Information

EFS ID	4801785
Application Number	10550381
Confirmation Number	3366
Title	Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
First Named Inventor	David Aitken
Customer Number or Correspondence Address	01095
Filed By	Daniel J. Woods/Cindy Klepacky
Attorney Docket Number	PN/A-33001A
Filing Date	21-SEP-2005
Receipt Date	17-FEB-2009
Application Type	U.S. National Stage under 35 USC 371

Application Details

Submitted Files	Page Count	Document Description	File Size	Warnings
33001IDS.pdf	6		512680 bytes	PASS
		Document Description	Page Start	Page End
		Information Disclosure Statement Letter	1	2
		Information Disclosure Statement (IDS) Filed (SB/08)	3	5
		Miscellaneous Incoming Letter	6	6
WO1989005642.pdf	27	Foreign Reference	896141 bytes	PASS
GB864536.pdf	6	Foreign Reference	561594 bytes	PASS
EP637449.pdf	5	Foreign Reference	314823 bytes	PASS
WO2001039779.pdf	47	Foreign Reference	2307422 bytes	PASS
WO2002003915.pdf	18	Foreign Reference	810433 bytes	PASS
ErnstMutschler.pdf	10	NPL Documents	590783 bytes	PASS
Merckmanual.pdf	30	NPL Documents	8619693 bytes	PASS
Zarnowski.pdf	2	NPL Documents	606065 bytes	PASS

Borowicz.pdf	8	NPL Documents	741054 bytes	◆ PASS
BorowiczDE.pdf	8	NPL Documents	741054 bytes	◆ PASS
Swiader.pdf	5	NPL Documents	259420 bytes	◆ PASS
Czuczwar.pdf	7	NPL Documents	119039 bytes	◆ PASS
Auberson.pdf	6	NPL Documents	348141 bytes	◆ PASS
WO1998017692.pdf	19	Foreign Reference	674349 bytes	◆ PASS
WO2003042182.pdf	10	Foreign Reference	418344 bytes	◆ PASS
CN1265889.pdf	4	Foreign Reference	245481 bytes	◆ PASS
Deckers.pdf	11	NPL Documents	1741559 bytes	◆ PASS
Dani.pdf	4	NPL Documents	353790 bytes	◆ PASS
fee-info.pdf	2	Fee Worksheet (PTO-06)	30135 bytes	◆ PASS

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application Under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

If you need help:

- Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail EBCC@uspto.gov for specific questions about Patent e-Filing.
- Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).
- If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
AITKEN ET AL.
INTERNATIONAL APPLICATION NO: PCT/EP04/003518
FILED: 2 APRIL 2004
U.S. APPLICATION NO: 10/550,381
35 USC §371 DATE: 21 SEPTEMBER 2005
FOR: COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS

Art Unit: 1615

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 21, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. These references are of record in the instant PCT application PCT/EP04/003518, copies are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9587



Daniel J. Woods
Attorney for Applicants
Reg. No. 59,864

Date: 2/17/09

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PN/4-33001A
APPLICATION NO.
10/550381
APPLICANT
AITKEN ET AL.
FILING DATE
September 21, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	89/05642	6/29/89	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	864 536	4/5/91	GB			<input type="checkbox"/>	<input type="checkbox"/>
	AO	0 637 449	2/8/95	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	01/39779	6/7/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	02/03915	1/17/02	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	DATABASE WPI Section Ch, Week 200066 Derwent Publications Ltd., London, GB; Class B05, AN 2000-673134 XP002291965 & CN 1 265 889 A (WANG X) 13 September 2000 (2000-09-13)
AS	Ernst Mutschler: "Arzneimittelwirkungen - Lehrbuch der Pharmakologie und Toxikologie" 1997, Wissenschaftliche Verlagsgesellschaft MbH Stuttgart, Stuttgart, XP002291963 page 252 - page 260 in particular p. 260
AT	Mark H. Beers, M.D., Robert Berkow, M.D.: "The Merck Manual" 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002291964 page 1406 - page 1408

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PN/4-33001A
APPLICATION NO.
10/550381
APPLICANT
AITKEN ET AL.
FILING DATE
September 21, 2005

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Dam M: "Summing Up Of The Success So Far Gained Through Choice Of Drugs Or Combinations Of Drugs" Acta Neurologica Scandinavica Supplementum, vol. 69, no. 99, 1984, pages 19-22, XP009035076 & 3RD Workshop On Memory Functions, Gothenburg, FEB. 4-6, 1983. ACTA Neurol Scand Suppl. ISSN: 0065-1427
DB	Deckers C L P et al: "Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed" Epilepsia 2000 United States, vol. 41, no. 11, 2000, pages 1364-1374, XP009035157 ISSN: 0013-9580
DC	Zemowski Tomasz et al: "NBQX: A selective AMPA antagonist enhances antiepileptic properties of common anticonvulsant drugs against maximal electroshock in mice" Polish Journal Of Pharmacology And Pharmacy, vol. 44, no. SUPPL., 1992, pages 258-259, XP009035158 & XI Congress Of The Polish Pharmacological Society And Of The German Society Of Pharmacology And Toxi, Gdansk, Poland; September 16-19, 1992 ISSN: 0301-0244
DD	Borowicz Kinga K ET AL: "Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats" Polish Journal Of Pharmacology, vol. 53, no. 2, March 2001 (2001-03), pages 101-108, XP009035159 ISSN: 1230-6002
DE	Borowicz Kinga K et al: "The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics" European Journal Of Pharmacology, vol. 281, no. 3, 1995, pages 319-326, XP002292362 ISSN: 0014-2999
DF	Swiader Mariusz et al: "Influence of LY 300164, an AMPA/kainate receptor antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice." Polish Journal Of Pharmacology, vol. 55, no. 1, January 2003 (2003-01), pages 103-107, XP009035160 ISSN: 230-6002
DG	Czuczwar S J et al: "LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs" European Journal Of Pharmacology 1998 Netherlands, vol. 359, no. 2-3, 1998, pages 103-109, XP002292363 ISSN: 0014-2999
DH	Auberson Y P ET AL: "N-phosphonoalkyl-5- aminomethylquinoxaline -2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists" Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 9, no. 2, 18 January 1999 (1999-01-18), pages 249-254, XP004152611 ISSN: 0960-894X
DI	
DJ	
DK	
DL	
DM	
DN	

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PN/4-33001A
APPLICATION NO.
10/550381
APPLICANT
AITKEN ET AL.
FILING DATE
September 21, 2005

Group

*EXAMINER: Initial of reference

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	98/17692	4/30/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CB	03/042182	5/22/03	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CC	1265889	9/13/00	CN			<input type="checkbox"/>	<input type="checkbox"/>
	CD						<input type="checkbox"/>	<input type="checkbox"/>
	CE						<input type="checkbox"/>	<input type="checkbox"/>
	CF						<input type="checkbox"/>	<input type="checkbox"/>
	CG						<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 509: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1615

AITKEN ET AL.

APPLICATION NO: 10/550,381

FILED: SEPTEMBER 21, 2005

FOR: COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR
THE TREATMENT OF NEUROLOGICAL DISORDERS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 101
East Hanover, NJ 07936-1080
(862) 778-9587
Date: 2/17/09



Daniel J. Woods
Attorney for Applicants
Reg. No. 59,864